BUSINESS
SRF: Building a specialty chemicals business block by block
BUSINESS
Aurobindo: Traction in complex generics is vital to its health
BUSINESS
Britannia: Advantage Supply Chain
BUSINESS
Lupin: A watershed year for the US business?
BUSINESS
The wait for Sun Pharma to rise gets longer
BUSINESS
Dabur Q4: Is elevated rural exposure Dabur’s Achilles heel?
BUSINESS
Aarti Industries Q4: Near-term uncertainty leads to capex deferral
BUSINESS
Dr Reddy’s: Primed by strong bets on complex pharma opportunities, good for risk takers
BUSINESS
RIL rights issue: Rights entitlements trade at premium; another capital market reform in place
BUSINESS
Proposed ban on some agrochemicals is negative for producers
BUSINESS
The reset of globalisation: How big is it an opportunity for India Inc? (Part 2)
India is certainly one of the main contenders for the shift in global trade away from China. But there are many challenges.
BUSINESS
The reset of globalisation: How big is it an opportunity for India Inc? (Part 1)
On the export front, the opportunity for Indian manufacturers are humongous if there is a sizeable shift in opportunities from China to India.
BUSINESS
Cipla: Respiratory pipeline adds oxygen, accumulate
BUSINESS
RIL: Bandwidth of technology investors expands with General Atlantic; Deleveraging on track
First, Facebook, then Vista and Silver Lake, and now General Atlantic. Jio continues to be a big draw for technology investors. The zero-debt goal for RIL has just got more fuel.
BUSINESS
Tata Consumer: Are all the positives priced in?
BUSINESS
Godrej Consumer Q4FY20: All hopes pinned on health and hygiene
BUSINESS
Sequent Scientific Q4: Ownership change can accelerate US plans
BUSINESS
Sequent Scientific: Private equity buyout to remove non-operational risk of pledged shares
BUSINESS
Solara Active Q4: gears up for shift in pharma production from China
BUSINESS
Marico Q4: Portfolio focus on essentials a positive, accumulate on declines
BUSINESS
Laurus Labs Q4: Improving product mix and strong execution drive growth
BUSINESS
Atul Q4: Pharma and agrochem to lead the way
BUSINESS
HUL Q4: Disappointing results, but crisis track record justifies premium valuations
BUSINESS
Reliance's rights issue: Shot in the arm for debt reduction efforts; zero debt target in sight
